Pneumococcal empyema and complicated pneumonias: global trends in incidence, prevalence, and serotype epidemiology by M. A. Fletcher et al.
REVIEW
Pneumococcal empyema and complicated pneumonias: global
trends in incidence, prevalence, and serotype epidemiology
M. A. Fletcher & H.-J. Schmitt & M. Syrochkina &
G. Sylvester
Received: 25 November 2013 /Accepted: 15 January 2014 /Published online: 23 February 2014
# Springer-Verlag Berlin Heidelberg 2014
Abstract This review evaluates the serotype epidemiology of
complicated pneumococcal pneumonia (CPP) during the pe-
riod 1990–2012. PubMed and EMBASE were searched using
the terms “empyema”, “complicated pneumonia”, “pleural
infection”, “necrotizing pneumonia”, “pleural effusion”,
“parapneumonic effusion”, “pneumatocele”, or “lung ab-
scess”; “pneumococcal” or “Streptococcus pneumoniae”;
and “serotype” for studies on the epidemiology of complicat-
ed pneumonias published from January 1, 1990 to October 1,
2013. Studies with data on incidence and serotypes were
included; reviews, case reports, and conference abstracts were
excluded. Of 152 papers, 84 fitted the inclusion criteria. A few
pneumococcal serotypes were predominant causes of CPP,
particularly serotypes 1, 19A, 3, 14, and 7F. CPP was a more
common manifestation of pneumococcal disease among older
(>2 years old) than younger children. The data support in-
creases in both reported incidence rates and proportions of
CPP in children and adults during the period 1990–2012;
specific increases varied by geographic region. The propor-
tions of serotype 3 and, particularly in Asia, serotype 19A
CPP have increased, whereas most studies show declines in
serotype 14. Serotype 1 has been a predominant cause of CPP
since 1990, while antibiotic resistance was infrequent among
serotype 1 isolates. The reported incidence and proportions of
CPP among pneumonia cases steadily increased from 1990 to
2012. Several factors might account for these increases, in-
cluding enhanced disease detection due to a higher index of
suspicion, more sophisticated diagnostic assays, and changes
in the prevalence of serotypes with capacity to invade the
pleural space that were not targeted by the 7-valent pneumo-
coccal conjugate vaccine (PCV7).
Introduction
Streptococcus pneumoniae is the most common cause of
pneumonia in children and a major cause of pneumonia in
adults worldwide [1, 2]. Among patients with pneumonia, as
many as half may develop pleural effusions (i.e., fluid in the
pleural space); of these, 5–10 % may progress to empyema
[3]. In general, “complicated pneumonia” refers to pneumonia
accompanied by pleural effusion. Empyema is a serious com-
plication characterized by pus and bacteria in the pleural space
[3, 4], whichmay progress to necrosis, cavitation, or fistulas in
the thoracic cavity. S. pneumoniae is the most common cause
of complicated pneumonia in children and a common cause in
adults [5, 6]. Other bacteria associated with acute complicated
pneumonias include S. pyogenes, S. milleri, Staphylococcus
aureus, Haemophilus influenzae, Mycoplasma pneumoniae,
Pseudomonas aeruginosa, other Streptococcus species, and,
less commonly, Klebsiella, Enterobacter, Proteus,
Salmonella, and Yersinia species [5].
The reported incidence and proportion of cases of compli-
cated pneumococcal pneumonia (CPP) in children and adults
have increased in recent decades [7–19]. This trend has been
described both before and after the introduction in 2000 of the
7-valent pneumococcal conjugate vaccine (PCV7; serotypes
4, 6B, 9V, 14, 18C, 19F, and 23F conjugated to CRM197) for
pediatric vaccination. A 23-valent pneumococcal polysaccha-
ride vaccine (PPV23) containing pneumococcal capsular
polysaccharides (serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V,
M. A. Fletcher (*) :H.<J. Schmitt




Pfizer, Inc., Yekaterinburg, Russia
G. Sylvester
Pfizer Inc., Collegeville, PA, USA
Eur J Clin Microbiol Infect Dis (2014) 33:879–910
DOI 10.1007/s10096-014-2062-6
10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F,
and 33F) was introduced in 1983 for the vaccination of
children and adolescents at high risk of pneumococcal disease,
but primarily older adults. Unlike the pneumococcal conju-
gate vaccines, PPV23 is not approved for children aged
<2 years. PPV23 in adults has been shown to have an impact
on bacteremic pneumococcal pneumonia, but not all-cause
pneumonia [20, 21]. More recently, the 10-valent pneumococ-
cal conjugate vaccine (PCV10; serotypes 1, 4, 5, 6B, 7F, 9V,
14, and 23F conjugated to non-typeable H. influenza protein
D, serotype 18C conjugated to tetanus toxoid, and serotype
19F conjugated to diphtheria toxoid) and the 13-valent pneu-
mococcal conjugate vaccine (PCV13; serotypes 1, 3, 4, 5, 6A,
6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F conjugated to
CRM197) were introduced beginning in 2009 (Table 1).
A limited number of pneumococcal serotypes have been
associated with CPP and pneumococcal empyema (PnEmp).
Changes in the serotype epidemiology of invasive pneumo-
coccal disease (IPD) and pneumococcal pneumonia have been
reported in recent years, with significant declines in incidence
and in the proportion of disease caused by PCV7 serotypes
and increases in the proportion of non-PCV7 serotype disease
[22–27]. Although these changes are suggestive of serotype
replacement, similar trends have also been reported in some
countries prior to the introduction of PCV7 [28, 29, 68].
The purpose of this review is to evaluate the serotype
epidemiology of CPP during the period 1990–2012.
Methods
PubMed and EMBASE were searched for studies on the
epidemiology and incidence of CPP published from January
1, 1990 throughOctober 1, 2013 using the terms: “empyema”,
“complicated pneumonia”, “pleural infection”, “necrotizing
pneumonia”, “pleural effusion”, “parapneumonic effusion”,
“pneumatocele”, or “lung abscess”; “pneumococcal” or
“Streptococcus pneumoniae”; and “serotype”. Studies with
data on incidence, prevalence (i.e., proportion of cases), or
serotypes were included; reviews, case reports, and confer-
ence abstracts were excluded. In addition, the references sec-
tions of relevant review articles were checked for studies not
identified during the online search.
The base population used for analyses varied by study. For
example, among studies of incidence or proportion of com-
plicated pneumonias or empyema, the base populations in-
cluded: hospitalized patients [13] or hospitalized patients with
community-acquired pneumonia (CAP) [19, 30–32]; pneu-
mococcal pneumonia [9, 16, 32–40]; IPD [10, 12, 17, 18,
41–49]; complicated pneumonia [7, 13, 50–54]; complicated
pneumonia with positive cultures [14]; CPP [55]; empyema
[56–61]; or empyema with fistula [62].
Table 1 Pediatric pneumococcal conjugate vaccine approval history for
the countries included in this review (Pfizer, data on file)
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Some studies described the clinical methodologies used to
identify pleural effusion or empyema prior to microbiological
identification. Retrospective studies used: diagnostic coding
[16, 19, 30, 31, 35, 52, 61]; records of chest radiographs [9,
33, 48, 50]; computed tomography (CT) [7, 9, 34, 50]; ultra-
sound [7, 34, 50, 56]; microbiologic culture records [13]; or
results at surgery [56]. One study reviewed “pleural effusion
data”, although no other details were specified [48]. Prospec-
tive studies used: thoracocentesis [39, 51, 53, 54]; CT, ultra-
sound, or chest radiograph plus clinical signs [58]; CT, ultra-
sound, or chest radiograph [32]; or physical examination and
chest radiograph [37, 60, 63]. One study did not specify the
diagnostic methodology [49].
Studies varied in the methodologies used to isolate
S. pneumoniae, including: culture of samples from the pleural
cavity [7, 13, 49–51, 54, 58, 62, 64–66], blood [32, 68–71],
blood and pleural cavity [9, 10, 14, 15, 17, 18, 30, 31, 34–36,
38, 41–48, 52, 53, 56, 57, 63, 72–90], or unspecified sites [33,
40, 91]; and, more recently, investigators used polymerase
chain reaction (PCR) or real-time PCR to identify
pneumococcal-specific genes (e.g., ply, LytA, rpoB, or wzg
[cpsA]) in samples from the pleural cavity [43, 46, 49, 51,
53–55, 58, 60, 64, 67, 87, 88, 90, 92–94], blood [15, 32, 37,
75, 95], blood and pleural cavity [88], or nasopharyngeal
aspirate [96]. A few studies applied immunochromatographic
pneumococcal antigen detection (Binax NOW®) from blood
or urine [15, 38, 51, 74, 77, 84].
Pneumococcal serotypes in blood or pleural fluid were
identified with the Quellung reaction (also referred to as
capsular swelling) [7, 12, 14, 15, 17, 18, 30, 31, 34–38, 40,
42–49, 56, 68, 69, 71, 73, 77, 82, 85–88, 90–93], dot blot [47,
71, 93], slide or latex agglutination [8–10, 40, 63, 65, 70, 72,
77, 80, 81, 83, 84, 97, 98], enzyme-linked immunoassays [55,
99], real-time PCR [32, 37, 43, 44, 46, 49, 51, 64, 65, 87, 88,
90, 93, 95], or multiplex PCR [54, 58, 60, 67, 74, 84, 92, 94,
97]. The Quellung reaction may include up to all the known
serotypes, whereas PCR is typically more limited in the sero-
types that can be identified. Some studies used more than one
methodology (e.g., initial serotyping of cultured isolates,
followed by PCR in culture-negative samples) [37, 65, 87,
88, 93, 94].
Definitions of penicillin susceptibility varied; some studies
used breakpoints established by the Clinical and Laboratory
Standards Institute (CLSI) in 2009 [53, 74, 83, 88, 90, 100],
whereas others used pre-2009 breakpoints [7, 9, 15, 17, 30,
34, 63, 73].
Results
A total of 152 papers were initially identified; 68 were ex-
cluded because there were no data on incidence or serotypes,
or they were case reports; consequently, 84 were included in
this analysis.
Table 2 presents data on the incidence and proportion of
CPP [7, 9, 10, 12–14, 16–19, 30–47, 49–62]. Trends and age-
related differences in the studies are discussed below.
Incidence
The incidence of any-cause empyema among children aged
<19 years in Utah (USA) (1994–2007) [30, 31] and Australia
(1998–2010) [19] ranged from 0.9 to 12.5 per 100,000 pop-
ulation, and tended to increase over time; the incidence was
highest in children aged 0–4 years (Table 2) [19]. Likewise, in
Spain from 1997–2001 to 2002–2006, the PnEmp incidence
was lower in children aged 5–17 years (0.5–1.3 per 100,000
population) as compared to younger children [12]. In 1996–
2001 and 2006–2009, the adult PnEmp incidence was higher
in those aged >65 years (3.5–4.8 per 100,000) than other adult
age groups (0.5–1.8 per 100,000) (Table 2) [17].
The incidence for PnEmp tended to increase from the late
1990s to the mid-2000s in children in the USA [10, 16] and
Spain [12], but remained lower in children aged 5–17 years
compared with younger children (Table 2) [12]. For example,
the PnEmp incidence among children aged <18 years in Utah
(USA) increased from 10.3 per 100,000 population in 1996–
2000 to 14.3 per 100,000 population in 2001–2003 [10], and
increased in children aged 2–4 years in the USA from 1.1 to
2.5 per 100,000 population from 1996-1998 to 2005–2007,
respectively [16]. In Spain from 1997–2001 to 2002–2006,
the PnEmp incidence increased from 2.2 to 9.2 per 100,000
population in children aged <2 years and from 1.5 to 9.2 per
100,000 population in children aged 2–4 years [12]. Of note,
two studies from Spain showed significant declines in the
PnEmp incidence following the introduction of PCV13 into
the pediatric immunization program: in one, from 6.73 to 4.14
Table 1 (continued)





PCV7, 7-valent pneumococcal conjugate vaccine; PCV10, 10-valent
pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal con-
jugate vaccine
a Dates refer to a national immunization program, unless otherwise
specified
bYear of introduction into immunization programs varied by province
c Physician choice program
d Private market only
e Switched to PCV13 in November 2010
f Included in the national immunization program in 2005
g Regional (city) mass vaccination programs

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































888 Eur J Clin Microbiol Infect Dis (2014) 33:879–910
per 100,000 from 2009–2010 to 2010–2011 (age <15 years)
[46]; in the other, from 5.72 to 3.12 per 100,000 population
from 2007–2010 to 2011–2012 (p=0.0019) (age <15 years)
[49], and from 3.57 to 2.66 per 100,000 population (p=
0.0224) (ages ≥12 to <24 months) (Table 2) [49].
Proportion of cases with CPP
Outcomes used as numerators for proportions of cases with
CPP ranged from more general (e.g., pulmonary complica-
tions, complicated pneumonia) to more specific (e.g., empy-
ema, cavitatory disease). Denominators varied, including hos-
pitalized patients, hospitalized patients with CAP, hospitalized
patients with pneumococcal CAP, or children with
parapneumonic PnEmp. In addition, the assessment methods
varied in sensitivity, which may have affected the reported
proportions. For example, in hospitalized children with em-
pyema in Australia, only 7.5 % of pleural fluid cultures, but
51.0 % of pleural fluid PCRs, were pneumococcal-positive
[58].
The proportion of cases of CPP or PnEmp among hospi-
talized children with pneumococcal pneumonia or IPD ranged
from 7.9 to 71.4 % (Table 2) and tended to increase over time
[9, 10, 12, 16, 18, 32–37, 41, 44–46, 49]. For example, the
proportions of cases of CPP or PnEmp in hospitalized children
with IPD in Spain increased from 6.9 % in 1997–2001 [12] to
65.4 % during 2007–2009 [10, 18, 41, 44–46, 49]. Among
hospitalized children with CAP in Utah (USA), the proportion
of cases of complicated pneumonia and empyema increased
from 13% in 1994 to 41% in 1997 [30]. Among children with
complicated pneumonia or empyema, the proportion of cases
of PnEmp as reported in several countries ranged from 0 to
54.4 %, although the sample sizes were often small [7, 13, 14,
49, 50, 52–60, 62].
Among hospitalized adults with pneumococcal CAP, the
proportions of cases with pleural effusion (PE) (15.2–19.5 %,
Spain) [38, 39] were higher than those for PnEmp (6.4 %,
Spain) [38] or necrotizing pneumonia (6.5–6.6 %, USA) [40].
Among hospitalized adults with IPD in Spain, 6.9–15.0 %
were diagnosed with PnEmp (Table 2) [17, 47].
Effect of age on the incidence and proportion of cases of CPP
The effect of age on CPP was not consistent across studies,
and age effects for incidence differed as compared to propor-
tion. In most studies, older children comprised a larger pro-
portion of those with CPP or PnEmp relative to other pneu-
mococcal diseases. In Utah (USA) (1997–2010), children
with CPP were significantly older than those with other forms
of IPD (37 months vs. 25 months; p<0.001) [18]. Among
children with pneumococcal pneumonia in the USA (1993–
2000), the proportion of cases with CPP increased with age
from 26.4% (ages 0–12months) to 53.0% (ages >61 months)
[34]. In contrast, in a study of children from four Asian
countries (Vietnam, China, Korea, and Taiwan), empyema
and PE were most common in the younger age groups, par-
ticularly those ≤4 years of age [13].
The pattern of age-specific incidence may differ from that
of the proportion of cases. For example, among hospitalized
children with IPD in Spain (1997–2006), the proportion of
cases with PnEmp increased with age from 6.9–17.9 % (ages
<2 years) to 21.4–33.3 % (ages 5–17 years), whereas the
PnEmp incidence declined with age from 2.2–9.2 per
100,000 population (ages <2 years) to 0.5–1.3 per 100,000
population (ages 5–17 years), which seems to parallel the
pattern of IPD incidence among children [12]. In particular,
in another study in Spain (2007–2012), the PnEmp incidence
was greater among children aged ≥24 to <60 months (8.55–
13.81 per 100,000 population) than among younger
(<12 months: 1.78– 1.36 per 100,000 population) or older
(5–15 years: 1.53–2.36 per 100,000 population) children [49].
In Spain (1996–2009), although adults aged 50–65 years
had a higher proportion of cases of PnEmp (17.3 %) than
adults aged >65 years (12.7 %), the PnEmp incidence was
lower among adults aged 50–65 years than those aged
>65 years (1.4 vs. 4.8 per 100,000 population, respectively)
[17], which is consistent with the trend of age-specific inci-
dence of IPD with aging.
Serotype epidemiology
Table 3 presents data on serotype epidemiology [7–9, 14, 15,
17, 18, 30–35, 37, 39–41, 43, 44, 46, 47, 49, 51–60, 62, 64,
66–69, 72, 73, 75–84, 86–91, 93, 94, 97, 99, 101, 102].
Globally, serotypes 1 and 19A exhibited strong associations
with pneumococcal PE [15, 52, 66, 69], PnEmp [10, 31, 43,
46, 49, 54, 57, 58, 60, 68, 72, 81, 83, 88, 90, 93, 101], or both
[32, 39, 44].
In Utah (USA) (2001–2010), CPP in children was caused
mainly by serotypes 1, 7F, 19A, and 3 (Table 3). Compared
with other serotypes, serotype 1 was significantly more likely
to cause CPP than other pneumococcal diseases (86 % vs.
29 %; odds ratio [OR], 14.0; p<0.001) [18]. Among children
with IPD in Spain (2002–2006), serotype 1 caused 29.6 % of
cases of PnEmp, compared with 11.1 % caused by PCV7
serotypes (NB, which were all serotype 14 isolates) (Table 3)
[101]. Similarly, among adults during 2006–2009 in Spain,
serotype 1 caused 32.7 % of cases of PE [39].
Serotype 19A also appears to be important, particularly in
the Asia-Pacific region. For example, serotype 19A caused
69.2 % and 71.0 % of cases of pneumococcal necrotizing
pneumonia and PnEmp, respectively, in children in Taiwan
[83], 46.2 % of PnEmp cases in children in Korea [54], and
36.4 % of PnEmp cases in children in Australia [58].
Serotypes varied in their prevalence as complicated versus
uncomplicated pneumonia. In children in Utah (USA) (1997–
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2006), serotype 3 was the most frequent cause of pneumococ-
cal necrotizing pneumonia (28.9 %; 11/38 cases), whereas
serotype 1 (22.6 %; 28/124 cases) was predominant in un-
complicated pneumococcal pneumonia [35]. Conversely,
among children with community-acquired invasive pneumo-
coccal pneumonia (IPP) (i.e., pneumonia with S. pneumoniae
isolated from blood or pleural fluid) in Italy (2007–2009),
serotype 1 caused a significantly higher percentage of CPP
than uncomplicated pneumonia (50 % vs. 18.2 %; p=0.005)
[32]. In children aged <18 years in Taiwan (1998–2010), the
proportions of cases of CPP caused by PCV7 and non-PCV7
serotypes were similar (51.6 % and 48.4 %, respectively), and
serotypes 14 and 3 were the most common serotypes (32.3 %
and 35.5 % of cases, respectively). Serotype 3 was the most
common serotype causing CPP compared with uncomplicated
lobar pneumonia (OR, 0.114; 95 % confidence interval [CI],
0.013–0.973) [48].
In children with any-cause empyema in the UK (2002–
2009), S. pneumoniaewas the most frequently isolated organ-
ism, found in 44 of 70 children (62.9 %) from whom an
organism was identified [62]. Serotype 3 was significantly
more common in pneumococcal bronchopleural fistula (10/
13 cases) compared with no fistula (1/15 cases) (p<0.0001),
whereas serotype 1 was the most common serotype among
cases without fistula (7/15 cases) and was not found among
those with fistula [62]. In children in England with cavitatory
d i sease compl ica t ing PnEmp or pneumococca l
parapneumonic effusion, the most common serotypes were 1
(4/11 cases, 36.4 %) and 3 (3/11 cases, 27.3 %) [55].
Among Spanish adults (2006–2009), serotype 1 was the
most frequent cause of CPP (32.7 %) and uncomplicated
pneumococcal pneumonia (31.2 %); the other frequent causes
of complicated pneumonia, in descending order of frequency,
were serotypes 19A, 3, 14, 5, and 12F (Table 3) [39]. In adults
in the USAwith pneumococcal pneumonia (n=351), serotype
3, the most common cause of pneumonia overall, was isolated
in 5 of 16 specimens (31.2 %) from patients with pneumococ-
cal necrosis; 10 other serotypes caused the remaining 11 cases
(Table 3) [40].
Serotype 1 undergoes periodic outbreaks, so it is possible
that increases in serotype 1 PnEmp may be associated with a
cyclic pattern [87]. Serotype 1 clones were analyzed in
PnEmp among children [31, 87, 101] and adults [47].
Multilocus sequence typing (MLST) analysis of pediatric
PnEmp cases in Utah (USA) suggested that replacement se-
quence types (STs) contributed to the increase in incidence of
pediatric PnEmp post-PCV7 [31]. Before 2001, only ST227
(serotype 1) was identified; by 2003, six additional STs were
associated with serotype 1, including a single-locus variant of
ST227. In contrast, among serotype 1 isolates causing pediat-
ric PnEmp in Spain (2004–2006), three clones were identified
(ST228, ST306, and ST304); these were historically well-
established clones [101]. A more recent study of pediatric
PnEmp in Spain (2003–2006) identified the same three sero-
type 1 clones in pleural fluid [87]. MLST types associated
with the increased incidence of pediatric PnEmp had been
present previously in Spain and elsewhere in Europe, and,
therefore, the increase in proportions of PnEmp (predominant-
ly serotype 1) was probably not associated with the emergence
of new clones or of capsular switching [87, 101]. For adults in
Spain (1996–2010), an increase in PnEmp incidence in other-
wise healthy adults with pneumonia was associated predom-
inantly with serotype 1, in particular, ST306 [47].
Antibiotic resistance
Antibiotic sensitivity data are available from CPP isolates,
which are predominately the serotypes 14, 1, and 19A; among
these three predominant PCV13 serotypes, only 19A tends to
be associated with antibiotic resistance (probably due to its
relationship with nasopharyngeal carriage).
Among children in Utah (USA) (1993–1999), PnEmp was
less likely than uncomplicated pneumococcal pneumonia to
be caused by penicillin-resistant pneumococci (16% vs. 48%;
p=0.0021); all serotype 1 isolates were penicillin-susceptible
[30]. For pediatric CPP in Tennessee (USA) (1996–2001), all
serotype 1 isolates (n=5) were susceptible to penicillin,
whereas 5 of 7 serotype 14 isolates (the most frequently
identified isolate in this sample) were penicillin-resistant [7].
(By contrast, in eight children’s hospitals in the USA (1993–
2000), the antibiotic resistance rates were similar among iso-
lates from CPP and uncomplicated pneumococcal pneumo-
nias [34].)
Serotype 19A is associated with reduced sensitivity to
antibiotics [15, 53, 83, 90]. In Spain, 11% of cases of pediatric
PnEmp were caused by serotype 19A; all three culture-
positive serotype 19A isolates were non-susceptible to cefo-
taxime, and two were also non-susceptible to parenteral pen-
icillin [90]. Other serotypes isolated in this study (1, 5, and 7F)
were susceptible to parenteral beta-lactams and showed low
rates of resistance to oral penicillin and erythromycin. In
another Spanish study (2003–2006), 8 of 27 pneumococcal
isolates from pediatric PnEmp showed reduced susceptibility
to penicillin; two serotype 19A isolates and one each of
serotypes 14 and 3 showed resistance to multiple antibiotics
[15]. Similarly, in Taiwan (2007–2011), serotype 19A isolates
from pediatric PnEmp had lower levels of susceptibility to
cefotaxime than non-19A isolates, although the 19A and non-
19A isolates had similar susceptibility to other antibiotics
[83]. In Taiwanese children with empyema (2008–2009), 4
of 8 pneumococcal isolates were penicillin-resistant (i.e., se-
rotypes 19A [n=3] and 14 [n=1]) [53].
Several studies evaluated the association of pneumococcal
conjugate vaccine introduction with antibiotic resistance among
pneumococcal serotypes associated with CPP or PnEmp. In
Israel (1990–2002), no penicillin-resistant pneumococci were
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isolated from pediatric CPP [14], whereas in Taiwan (1995–
2003), more pneumococcal isolates from pediatric CPP than
from lobar pneumonia were intermediately susceptible or resis-
tant to penicillin [9]. In a subsequent study (1996–2005), the
penicillin resistance rates in PnEmp declined from 21% to 12%
(p=0.3) following PCV7 introduction [73]. Similarly, in Spain
(2005–2009), all pneumococcal isolates (n=34) from pediatric
PnEmp were susceptible to penicillin [88].
In Spanish adults (2001–2009), significantly higher pro-
portions of penicillin-susceptible isolates (p=0.013) were
identified from CPP compared with uncomplicated pneumo-
coccal pneumonia, which was associated with a higher rate of
erythromycin resistance (p=0.033) [74]. Among adults in
Spain with IPP, antibiotic resistance decreased and antibiotic
susceptibility increased between 1996–2001 and 2005–2009,
significantly so for penicillin (p=0.01) [63]. Likewise, among
adults with IPP in Spain (1996–2009), the proportion of cases
caused by penicillin-susceptible pneumococcal strains in-
creased from 71.7 % to 80.3 % (p=0.012), and susceptibility
to other antibiotics also trended upward [17].
Effect of age on serotype epidemiology
Age-based differences were observed in pneumococcal sero-
type proportions. In France (2007), both serotypes 1 (5/10
isolates) and 19A (5/10 isolates) were uniquely isolated from
pleural fluid in children with IPD, whereas from pleural fluid
in adults, the most frequent was serotype 19A (4/12 isolates)
[97]. In Spanish studies, serotype 1 was associatedwith IPD in
older children, whereas serotype 19A predominated in youn-
ger children [44, 49, 87, 90]. In Spain (2007–2009), among
children aged 3–59 months with IPD, serotype 1 was the most
frequent cause of PnEmp (24.9 % of all cases), and serotype 1
IPD was significantly more common in children aged 24–
59 months than those aged 3–23 months (adjusted OR, 7.70;
95 % CI, 2.12–10.38) [44]. Serotype 19A-related IPD was
noted to be more common among children aged <24 months,
although the proportion of cases with PnEmp in this age group
was not specified, and serotype 19Awas also associated with
PnEmp (14.3 % of all cases). In another Spanish study (2003–
2006), serotypes 1, 5, 7F, and 14 (i.e., serotypes with higher
invasive disease potential) were more frequent causes of
PnEmp in older children (median ages 56 months vs. 24
months; p=0.0001) compared with serotypes 6A, 9V, 19A,
and 23F (i.e., serotypes with low invasive disease potential)
[87]. This pattern was also evident in pediatric pneumonia in
Italy (2007–2009): serotype 1 was only detected in children
aged >2 years and was the predominant serotype associated
with CPP (50 % of cases), whereas serotype 19Awas signif-
icantly associated with younger age [32]. In Spanish children
with PnEmp (2007–2009), serotype 1 was more common in
children aged >36 months, serotype 3 was more common in
children aged 24–36-months, and serotype 19A was more
common in children aged <24 months [90]. More recently,
in a Spanish study of children aged <15 years with PnEmp
(2007–2012), the median overall age (52.0 vs. 44.0 months;
p=0.028) and the age of children with serotype 1 disease (74.0
vs. 49.5 months; p=0.002) was significantly higher one year
after the introduction of PCV13 (2011–2012) compared with
2007–2010 [49].
Discussion
The reported proportion of cases of CPP and PnEmp has
increased over the past several decades. For example, among
children aged <18 years with IPD in Utah (USA), the most
common form of IPD had been bacteremia without focus
(37 %) during 1997–2000, whereas by 2001–2010, CPP
became the most common form of IPD (33 %); the proportion
of CPP increased from 17 % (22/128 cases) to 33 % (127/385
cases) (p<0.001) [18]. Among hospitalized children with IPD
in Barcelona (Spain), the mean number of cases of PnEmp
increased significantly from 1998–2001 to 2002–2005 (15 vs.
43, respectively; p<0.02) [101].
Serotypes 1, 19A, 3, 14, and 7F predominated as causes of
CPP and empyema. For example, in the USA (1993–2000),
the most frequent serotypes causing pediatric CPP were sero-
types 14 (29.1 %) and 1 (24.4 %) [34]. In another study in the
USA (1996–2001), serotypes 14 (35.0 %), 1 (25.0 %), and
19A (15.0 %) were the most frequent causes of CPP [7]. In a
study in Italy among children with CPP (n=35), serotypes 1
(50.0 %), 3 (13.9 %), and 19A (11.1 %) predominated [32].
After the introduction of PCV7 into pediatric immunization
programs, several studies reported increases in the proportion
of CPP caused by non-PCV7 serotypes, particularly serotypes
1, 3, 7F, and 19A [17, 18, 31, 35, 50, 52]. In Barcelona
(Spain), the proportion of serotype 19A pediatric PE increased
from none (0/7) in 1997–2001, to 1/13 cases (8 %) during
2002–2004, to 6/34 cases (18 %) during 2005–2007; these
data also reflect an increase in the overall number of pediatric
PnEmp cases [86]. PCV7 serotypes and non-PCV7 serotypes
caused similar proportions of cases of CPP (51.6 % and
48.4 %, respectively) in children in Taiwan during a period
(1998–2010) when PCV7 immunization rates were low (i.e.,
in 2007, 15.9 % of children aged <5 years had received ≥1
dose), although serotype 3 was significantly more likely to
cause CPP compared with lobar pneumonia [48]. While fewer
data are available for PnEmp in adults, a Spanish study
reported significant increases from 1996–2001 to 2005–
2009 in the PnEmp incidence (0.5 to 1.6 cases/100,000 pop-
ulation; p <0.001) and the serotype 1 PnEmp incidence (0.1 to
0.8 cases per 100,000 population; p<0.001) in adults aged
18–50 years [17]. In England, the serotype 19A incidence for
pediatric CPP increased significantly from 0.48 to 2.02 per
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1,000,000 children from 2006–2007 to 2010–2011 (incidence
rate ratio, 4.17; 95 % CI, 1.53–14.2) [94].
Although in some studies the emergence of serotypes 1,
19A, 3, and 14 in CPP and PnEmp has corresponded to the
years following the introduction of PCV7 [17, 18, 31, 35, 50,
52, 86], a few studies demonstrated that their increasing role in
CPP and PnEmp began prior to the introduction of PCV7 [28,
29, 68]. For example, in a study of IPD in Spain (1989–2008),
the proportion of cases of IPD caused by serotype 1 was
increasing prior to the introduction of PCV7, and this trend
continued after the introduction of PCV7 (2 %, 8.6 %, 14.9 %,
and 23.8 % of cases in 1989–1993, 1994–1998, 1993–2003,
and 2004–2008, respectively [p<0.001]) [68]. This suggests
that emergence involves more than simply serotype replace-
ment following PCV7 introduction; characteristics particular to
certain serotypes, such as differences in antibiotic sensitivity or
their propensity to cause pleural infection, may be responsible
for these increases. In addition, several studies established a
relationship between the proportion of CPP and age that con-
trasts with the age-specific incidence of IPD [32, 40, 44, 49, 87,
90, 97], which may suggest an interaction between the propen-
sity of given serotypes to infect and the age-dependent suscep-
tibility of patients to infection by these same serotypes.
Recent data suggest that PCV13 may impact on pediatric
PnEmp caused by serotypes associated with CPP, such as 1
and 19A. In Spain, where PCV13 was introduced in 2010, the
incidence of pediatric PnEmp caused by serotypes targeted by
PCV13 declined significantly from 2009–2010 to 2010–2011
(5.52 vs. 3.55 per 100,000 population; p=0.049), mainly due
to reductions in serotypes 1 (2.81 vs. 2.07 per 100,000 popu-
lation) and 19A (1.51 vs. 0.69 per 100,000 population) [46].
More recently, in children aged <15 years in Spain, the PnEmp
incidence declined significantly (p=0.0019) from 5.72 to.
3.12 per 100,000 population in, respectively, 2007–2010 and
2011–2012, while the median age of children with PnEmp
was greater in 2011–2012 (i.e., following PCV13 introduc-
tion) than 2007–2010 (47.0 vs. 42.0 months; p=0.032) [49].
Although this review has recapitulated the basic epidemi-
ology of CPP (including PnEmp) over the past several de-
cades, the increased use of more specific diagnostic imaging
(e.g., CT and ultrasound) in recent years may affect the re-
ported rate of PE and empyema because of the more accurate
identification. Improved diagnostic methodologies, clinical
(ultrasound or CT vs. physical examination or chest X-ray)
and microbiological (e.g., PCR vs. culture), as well as in-
creased awareness of and vigilance for PE and empyema
may have resulted in an apparent increase in the proportion
of CPP over the time period included in this analysis, which,
given the limitations of the retrospective nature of this analy-
sis, may be a confounding factor in the determination of any
true increase in the proportion of CPP.
This review is also limited by the fact that many of the
studies used culture to identify pathogens. Culture may be less
than ideally sensitive to the presence of specific pathogens
because of factors such as prior antibiotic use or other diffi-
culties in culturing pathogens. In recent years, PCR has been
applied to identify the pneumococci causing CPP and to
identify serotypes in culture-negative specimens [32, 59, 64,
84, 87, 93]. As antibiotic treatment may reduce the likelihood
of detecting bacteria via culture, PCR is useful in detecting
pneumococci in culture-negative samples from patients previ-
ously treated with antibiotics. For example, in a Spanish study
of culture-negative pleural fluid specimens from children with
empyema, PCR typing identified eight different serotypes
(i.e., serotypes 1, 3, 5, 7F/7A, 8, 14, 19A, and 19F/B/C) in
52 of 67 culture-negative pleural fluid samples from children
with PnEmp, with a sensitivity of 96.0 % and a specificity of
98.6 % [93]. Spanish pediatric empyema patients with
S. pneumoniae culture-negative/PCR-positive samples were
found to be significantly more likely to have received antibi-
otics than those with culture-positive samples (92 % vs. 53 %,
respectively; p<0.0001) [87]. Rapid pneumococcal antigen
detection by means of immunochromatography has also been
used to detect pneumococci in isolates from patients with
empyema [51]. In hospitalized children with parapneumonic
effusion, conventional microbiologic culture of pleural fluid
samples detected pneumococci in 15 of 55 isolates, real-time
PCR detected pneumococci in 13 of 16 culture-negative iso-
lates (81.2 %), and immunochromatographic testing detected
pneumococci in 24 of 27 culture-negative isolates (88.9 %)
[51]. Such molecular methods may complete the information
available on changes in the IPD and CPP serotype epidemi-
ology over time.
Finally, most of the studies reviewed here used retrospec-
tive database analyses to identify cases of CPP and PnEmp.
The specificity of information in these databases could vary,
as cases may have been missed due to misclassification. In
recent years, increased awareness of CPP and PnEmp has led
to prospective surveillance studies, which may enhance dis-
ease identification. In addition, studies used different
breakpoints to determine penicillin sensitivity, making it dif-
ficult to compare antibiotic resistance results.
In conclusion, the reported proportion of cases of CPP and
PnEmp due to non-PCV7 serotypes has increased over the
past several decades in countries that introduced PCV7 into
the pediatric immunization program. Whether this increase
reflects the advent and wider use of more specific diagnostic
methods and increased awareness due to research initiatives,
or if it, indeed, represents a true increase in disease incidence,
is unclear. Several factors may account for these greater pro-
portions, including enhanced disease detection due to a higher
index of suspicion and more sophisticated diagnostic assays,
as well as the prevalence of certain non-PCV7 serotypes that
are capable of invading the pleural space.
It is established that reductions in the proportion of PCV7
serotype CPP have been observed in countries using PCV7.
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Most serotypes associated with CPP and PnEmp—particular-
ly serotypes 1, 19A, 3, and 7F—are targeted by PCV13,
which was registered for pediatric vaccination from 2009
and for adult vaccination from 2011. Early reports suggest
declines in the incidence and proportion of cases of vaccine
serotype CPP post-PCV7 introduction, and then further with
PCV13, although studies are ongoing.
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